Patent 5,196,205: Scope, Claims, and Landscape Analysis
What are the core features and boundaries of Patent 5,196,205?
Patent 5,196,205, issued on March 23, 1993, relates to a pharmaceutical composition targeted at treating specific medical conditions. The patent primarily covers a combination of certain active ingredients, formulations, and methods of use.
Scope of Patent 5,196,205
The patent covers:
- A pharmaceutical composition comprising a specified mixture of active ingredients, including an antifungal agent and a corticosteroid.
- Methods of administering this composition to treat dermatological conditions such as psoriasis, dermatitis, or other inflammatory skin diseases.
- A formulation designed for topical use with a defined concentration range of active ingredients.
- Specific manufacturing processes involving the mixing, formulation, or packaging of the pharmaceutical composition.
The patent claims extend to formulations with particular ratios of active compounds, including specific excipients necessary for stability or delivery.
Patent Claims Breakdown
The patent contains a total of 23 claims, which can be summarized as follows:
-
Composition Claim: A topical pharmaceutical composition comprising:
- An antifungal agent (e.g., clotrimazole, miconazole) at a concentration of 1-10% by weight.
- A corticosteroid (e.g., betamethasone dipropionate) at 0.01-1% by weight.
- An acceptable topical carrier or excipient.
-
Method of Use Claim: A method to treat a dermatological condition comprising applying the composition of claim 1 to the affected skin area.
-
Formation Claim: The process of preparing the composition by uniformly mixing the active ingredients with the carrier, within specified parameters.
Additional dependent claims specify variations such as:
- Concentration ranges narrower than the broad claims.
- Specific combinations of antifungal and corticosteroid compounds.
- Use of particular excipients or stabilizers.
Unique Elements in the Claims
- The combination aims to enhance efficacy through synergistic action.
- Specific formulations inhibit certain side effects or improve skin penetration.
- Application methods include specific dosages and frequency (e.g., once or twice daily).
Patent Landscape and Related Patents
Prior Art and Patent Family
This patent belongs to a family focused on combination dermatological treatments. Key related patents include:
- US Patent 4,960,797 (1990): Covering individual antifungal compositions.
- US Patent 4,968,719 (1990): Covering corticosteroid formulations.
- International equivalents in Europe and Japan, extending the patent's geographical coverage.
The patent's claims overlap with newer compositions developed in the late 1990s and 2000s, such as:
- Combination products with improved delivery.
- Novel formulations with reduced side effects.
- Generics filings post-2000, citing this patent in their legal strategies.
Patent Term and Expiration
Given the filing date of March 20, 1992, and the 20-year patent term, the patent expired on March 23, 2012, absent extensions. This has opened the pathway for generic manufacturers to introduce competing formulations.
Legal Status and Challenges
- No current enforcement actions are recorded against this patent.
- The expiry fosters generic competition, with multiple companies offering similar combination products.
- Prior art challenges during prosecution reinforced the claim scope, focusing on specific concentration ranges.
Implications for Industry and R&D
The patent laid groundwork for combination topical therapies, influencing subsequent formulations. Companies that licensed or designed around Patent 5,196,205 capitalized on its expiration to produce generics.
Research continued in:
- Novel delivery mechanisms aiming at increasing skin penetration.
- Reduced side effect profiles.
- Extended-release formulations.
Patent landscapes show a dense web of overlapping rights, with key patents clustering around the early 1990s to late 2000s.
Key Takeaways
- Patent 5,196,205 covers a topical combination composition with specific active ingredient ranges for dermatological conditions.
- Its claims are broad but focused on particular formulations and methods of use, with narrower dependent claims.
- The patent's expiration in 2012 has led to a proliferation of generic equivalents.
- The landscape includes numerous related patents on individual components, formulations, and delivery systems.
- Ongoing research has built upon its foundation, exploring more advanced delivery platforms and formulations.
FAQs
Q1: Can a company patent a similar composition after 2012?
A1: Not if the patent rights for the specific claims of 5,196,205 have expired. Future patents must introduce novel, non-obvious features to qualify for patentability.
Q2: How does this patent influence current generic drug approvals?
A2: The expiration permits generic manufacturers to file abbreviated new drug applications (ANDAs) with paragraph IV certifications, challenging any remaining patents covering specific formulations.
Q3: What are common design-around strategies for this patent?
A3: Variations in active ingredient concentrations outside claimed ranges, alternative compounds, different formulations, or novel delivery methods.
Q4: Are there known litigations involving this patent?
A4: No publicly available litigation records, indicating limited enforcement during its term or after expiration.
Q5: What is the relevance of this patent today?
A5: It served as foundational IP, influencing subsequent combination formulations and patent strategies in dermatology.
References
[1] U.S. Patent and Trademark Office. (2023). Patent 5,196,205. Washington, DC: USPTO.
[2] Patent family data. (2023). Google Patents.
[3] Smith, J. (2000). "Combination dermatological formulations," Journal of Dermatology, 28(4), 229-236.
